Medicenna Therapeutics Corp.
MDNAF
$0.31
-$0.02-7.02%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.87% | -13.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.32% | 3.92% | |||
| Operating Income | 8.32% | -3.92% | |||
| Income Before Tax | -17.53% | 2.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.53% | 2.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.53% | 2.74% | |||
| EBIT | 8.32% | -3.92% | |||
| EBITDA | 8.37% | -3.95% | |||
| EPS Basic | -13.15% | 2.67% | |||
| Normalized Basic EPS | -13.16% | 2.98% | |||
| EPS Diluted | -13.15% | 2.67% | |||
| Normalized Diluted EPS | -13.16% | 2.98% | |||
| Average Basic Shares Outstanding | 3.87% | 0.00% | |||
| Average Diluted Shares Outstanding | 3.87% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||